SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ImmunoGen -- Ignore unavailable to you. Want to Upgrade?


To: nigel bates who wrote (4639)1/8/2004 7:18:44 AM
From: nigel bates  Respond to of 5665
 
ImmunoGen loses 2 partners in cancer drugs
Thursday January 8, 6:46 am ET

NEW YORK, Jan 8 (Reuters) - ImmunoGen Inc. (NasdaqNM:IMGN - News) said on Thursday two of its partners are abandoning co-development of cancer drugs with the biotechnology company, moves that will increase its expenses for the fiscal year ending in June 2005.

ImmunoGen said it would retain full rights to one drug after previously sharing them with Franco-German drugmaker Aventis (Paris:AVEP.PA - News), and would move the drug into Phase II testing alone.

Vernalis Plc (London:VER.L - News) will continue two clinical trials already underway with a second experimental treatment, but ImmunoGen will take over future development of that drug, too...